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Abstract 
Since the 1990s, developments in the field of genetics have led to many questions on the 
use and possible misuse of genetic information. ‘Genetic discrimination’ has been defined 
as the differential treatment of asymptomatic individuals or their relatives on the basis of 
their real or assumed genetic characteristics. Despite the public policy attention around 
genetic discrimination, there is currently still much confusion surrounding this 
phenomenon. On the one hand, there is little evidence of the occurrence of genetic 
discrimination. On the other hand, it appears that people remain concerned about this 
theme, and this fear influences their health and life choices. This article makes use of a 
systematic literature review to investigate what is already known about the nature, extent 
and background of these fears and concerns. The 42 included studies have found 
considerable levels of concerns about genetic discrimination. Concerns dominate in 
insurance contexts and within personal interactions. The extent of concerns appears to 
vary depending on the type of genetic illness. Furthermore, installed laws prohibiting 
genetic discrimination do not seem to alleviate existing fears. This raises important 
questions as to the origins of these fears. Based on the findings, recommendations for 
future research are made. Firstly, research on the background of fears is needed. Secondly, 
future research needs to assess more fully all different forms (e.g. direct and indirect) of 
genetic discrimination. Finally, it has to be studied whether genetic discrimination is a 
form of discrimination that is distinguishable from discrimination based on an illness or 
disability. 
 
 Keywords: Genetic discrimination, fears for genetic testing, systematic literature review, 
social implications of genetics, insurance 
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INTRODUCTION 
Developments in the field of genetics have started to accelerate thanks to the Human 
Genome Project (1990-2003), a large-scale research project in which research groups 
from around the world worked together to obtain more insight into the human genome.1 
Alongside an expansion in scientific knowledge on genetics, time and money were also 
invested in the investigation of the possible social, ethical and legal implication of genetic 
developments, better known as ELSI issues.2, 3 One often cited ELSI issue is the problem 
of genetic discrimination. This is usually defined as “the differential treatment of 
asymptomatic individuals or their relatives on the basis of their real or assumed genetic 
characteristic".2, 4 There exists a high level of concern about this form of discrimination.5, 
6 Since the 1990's, policymakers have reacted to this threat of genetic discrimination and 
the accompanying worries by developing regulations.7 The establishment of such 
regulations had to meet several aims: prohibit genetic discrimination, reduce the 
accompanying fear, and prevent people from refusing to take a genetic test or to 
participate in genetic research out of fear for genetic discrimination.8 An overview of the 
existing regulations can be found in the articles of Joly et al.7 and Van Hoyweghen.9 
The results of the systematic literature review from Joly et al. suggest that there is 
insufficient unequivocal evidence whether or not genetic discrimination is actually 
present in the context of life insurance.10 In addition, the literature highlights the 
shortcomings of those studies in which evidence is given for genetic discrimination, in 
the insurance but also in the employment and the family, social and public context. These 
latter studies often contain methodological flaws, complaints about genetic discrimination 
prove to be exaggerated5, 11, 12, 13 and what is described as evidence is often merely 
anecdotal.3, 12 Nevertheless, it is suggested in the literature that the concern that personal 
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genetic information can and will be misused does exist.8, 14 Because of their concern, 
some choose to only undergo genetic testing anonymously, to turn to commercial 
companies which offer what is called direct-to-consumer testing, or to simply not take a 
genetic test.15 They thereby hope to keep personal genetic information out of the hands 
of third-parties. However, these people then miss out on the positive consequences of a 
genetic test, such as prevention or treatment. These precautions may cause additional 
stress.11 An illustration of this is the story of a woman with a family history of Alpha-1-
antitrypsin deficiency in the US.16 She was afraid that she would be unable to get health 
insurance or a job if a positive genetic test for the aforementioned genetic disease would 
be listed on her medical records. She therefore decided to get the genetic test done through 
a commercial company. She concealed the positive result, and tried to keep the illness 
under control herself. This continued until she realised that concealing the genetic 
condition was harming her health. 
Given the lack of evidence of genetic discrimination on the one hand, and the fears on 
the other hand, it appears necessary to investigate what is already known about concerns 
and fears surrounding genetic discrimination. What research has been conducted, and 
what do these studies teach us about what lies behind these concerns? In the rest of this 
article, we discuss our systematic literature research on the fears and concerns for genetic 
discrimination.  
 
MATERIALS AND METHODS 
The aim of this article is to produce clarity regarding existing knowledge on concerns and 
fears for genetic discrimination. Such an overview is necessary as researchers have 
usually investigated this topic in the context of only one single genetic mutation and/or 
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one single geographic region. Because of this, very specific information on the fears of 
genetic discrimination is available, but insight into global trends is currently absent. A 
systematic literature review of existing studies is the accepted method to bring these 
trends to light. It is a research method in which scientific studies are compared in a 
systematic and repeatable way.17 Alongside the creation of clarity, the results of a 
systematic literature review can also help determine the right direction for future research.  
One important step when conducting a systematic literature review is the inclusion of 
relevant studies. In order to standardise the literature search, we decided upon several 
criteria.17 Firstly, the included studies had to conduct research on concerns or fears about 
genetic discrimination. This was understood very broadly. For example, it is possible that 
the results of a study analysing the barriers to participation in genetic testing demonstrate 
that concern regarding discrimination in insurance is an important barrier for many 
respondents; such a study would be included in our review. Secondly, a substantial part 
of each included study should discuss fears and concerns of genetic discrimination; this 
should be reflected by mention of fears or concerns of genetic discrimination in the title 
or abstract. Lastly, it was necessary that the included studies dealt with the experiences 
and perceptions of those who could become the victim of genetic discrimination. Studies 
were not included on the basis of specific regions, genetic conditions or contexts of 
genetic discrimination, such as insurance or employment, because we suspect that the 
scope of current research is relatively limited. If subsequently the collected studies should 
appear to be too wide-ranging, additional inclusion criteria were applied. 
The literature search (figure 1) began with entering (a combination of) specific search 
terms (‘genetic’, ‘discrimination’, ‘fears’, ‘concerns’, ‘insurance’, ‘employment’, 
‘genetic test’, ‘study’ and ‘research’) into various medical and social science databases. 
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These databases were: PubMed, Google Scholar, Social Science Research Network and 
Web of Science (Social Sciences Humanities Proceedings and Social Sciences Citation 
Index / SSCI). This resulted in a provisional collection of 1813 articles. This collection 
was only ‘provisional’ because we considered it to be reasonable that, on the one hand, 
additional studies might be included based on references in the already included articles 
and, on the other hand, some of these studies might be rejected after content analysis as 
not containing relevant information.  
In a second phase, we searched for the abovementioned search terms in the title and 
abstract of each article. The collection of included studies was hereby reduced to 48 
articles. Subsequently, the already included studies were used to search for additional 
relevant studies. The bibliographies were gone through, and similar studies were found 
using Google Scholar. This resulted in eight extra studies. In the following phase, a 
thorough content analysis was conducted. The 56 articles were read several times, and a 
data extraction form, which outlines of each study was drawn up by the first author (AW). 
This form outlines the research aims, methodological choices, outcomes of interest and 
other relevant information15 and facilitates the organisation and comparison of results. 
The second author (IVH) commented on the data collection, the analysis process and the 
results were reviewed for accuracy. During the content analysis, 14 articles turned out not 
to be relevant for our research, and were excluded. It is typically difficult to determine if 
any studies have been missed, but we can conclude that the search strategy has been 
conducted with enough precision that all relevant articles have been identified.  
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RESULTS 
Scope and context 
Our search strategy resulted in a total of 42 studies. Table 1 offers an overview of the 
most important characteristics of these studies. The included articles span 19 years of 
scientific research (1996-2014; figure 2). This means that research on fears about genetic 
discrimination is relatively recent, which is not surprising given that developments in 
genetics only started accelerating in the last 30 years. Several other trends in the research 
conducted to date are revealed. For example, there is a lack of diversity in the countries 
or regions studied (figure 3). More than half of the research has been conducted in the 
United States, followed by a few studies in Canada and Australia. European research is 
limited to two studies, in the Netherlands and Germany respectively. Diversity in the 
countries is possibly significant because legislation on the use of genetic information and 
the type of healthcare system – private or public – differs from country to country.8, 9 
An overview also reveals that studies usually investigate the fear for genetic 
discrimination in the context of only one genetic mutation. A total of 19 different genetic 
mutations are mentioned, which can be divided into two categories. On the one hand are 
monogenic diseases, typified by a relatively conclusive genetic test due to the fact that 
the genetic component completely determines the development of symptoms. On the 
other hand are multifactorial diseases where a combination of a range of genetic factors 
and non-genetic factors determine whether or not the illness will manifest. The results of 
genetic tests for this second type of disease are far less unambiguous. In addition, genetic 
diseases differ in terms of the implications of a positive test result, the clinical profile, 
and prevention and treatment possibilities. The different characteristics of genetic 
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diseases might impact the type or degree of concern and the existence of genetic 
discrimination.11 
A further trend relates to the lack of research into genetic discrimination in the 
interpersonal sphere – for example, by family members or friends.8 Only 6.06% of studies 
have researched this form of discrimination (figure 4). The remaining studies focused on 
concerns about institutional discrimination – by insurers and employers – or 
discrimination in general. Furthermore, it can be noted that the research aims vary across 
the 42 studies. Research into concerns about genetic discrimination was the main 
objective in only six of the studies. In addition, it is striking that in the majority of the 
studies, data was collected by means of a survey. Since we wish to gain insight into the 
underlying reasons for discrimination fears, it is necessary to conduct more qualitative 
research. Related to this, considerable diversity is noticeable when comparing the applied 
definition of genetic discrimination. In the majority of studies it is not made explicit how 
genetic discrimination is defined, which makes the comparison more complex.  
This initial overview is valuable as it reveals the characteristics of the studies that have 
been conducted to date. Fears for genetic discrimination appear to have hardly been 
researched in Europe, Asia, South-America and Africa. Moreover, the topic has only been 
studied in a limited number of domains, in terms of geography and in terms of the context 
(institutional vs. interpersonal discriminating actors). In the rest of this article, we present 
specific results on fears and concerns of genetic discrimination. 
 
There is a real concern about genetic discrimination 
A first important trend is that all of the included studies have shown that concerns about 
genetic discrimination are present in the studied population. For example, Bombard et al., 
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in their research on people at risk of carrying the genetic mutation that causes 
Huntington’s disease, found that 86% of respondents feared genetic discrimination.18 
Other studies determined that genetic discrimination is one of the barriers mentioned most 
often for undergoing a genetic test.19-38 In the study of Kass et al. a person at risk for colon 
cancer stated “I would not be tested for any genes for the fact that someone can use it and 
I wouldn’t be covered for it.’’ (p. 712).38 None of the studies refuted the existence of such 
fears. However, the size of the fear did vary between studies. It is difficult to know which 
factors could explain this difference as the studies differ on so many characteristics.  
In addition, the results from nine studies suggest that concerns about genetic 
discrimination are greater than the actual occurrence of discrimination.18, 32, 39, 40-45 
McKinnon et al. in their study on carriers of a BRCA gene and the gene for Lynch 
syndrome in the United States stated for instance that fear for genetic discrimination in 
the context of insurance is common, but the data collected do not provide any evidence 
that discrimination on a large scale is actually occurring.43 So what is the background of 
these fears and concerns? We will revisit this question later in the article. 
 
One genetic disease is not like another 
Fear for genetic discrimination has been studied in the context of 19 different genetic 
mutations to date. The specific genetic disease studied appears to have an impact on the 
degree of fear. For example, the fears of people who carry a genetic mutation for 
Huntington's disease, as reported in various studies8, 18, 24, 42, 46, 47, appears to be 
systematically greater than the concern for genetic discrimination reported by potential 
carriers of a genetic mutation that can cause breast and ovarian cancer.21, 28, 29, 33, 40, 41, 43, 
48, 49 
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The research of Klitzman compares multiple genetic diseases. A suggestion is made 
as to why concerns and experiences of discrimination might differ depending on the 
disease confronting the individuals studied.11 Three genetic diseases (Huntington’s 
disease, breast cancer and Alpha-1-antitrypsin deficiency) which differ in terms of 
prevalence and treatment possibilities were selected. Through the selection of different 
diseases it was aimed to study the full range of issues and perspectives that may emerge. 
Certain diseases appear to be more readily associated with stigma or discrimination, 
regardless of whether they are genetic or not. For example, Huntington’s disease can 
cause non-specific, non-diagnostic psychiatric problems possibly resulting in 
interpersonal difficulties. The disease could result in negative differential treatment, not 
because of the genetic character but because of these behavioural problems. This possibly 
influences the existence and fear of different forms of discrimination. It is often difficult 
to distinguish between these different forms of discrimination. Individuals at risk for 
Huntington's disease rather experience these forms as a whole in daily life.24 
 
Fear for genetic discrimination resonates most in context of insurance 
The results from various studies suggest that the concern of becoming the victim of 
genetic discrimination is greater in insurance contexts than in the context of employment. 
For example, Erwin et al. have investigated the perceptions and experiences of genetic 
discrimination of potential carriers of Huntington’s disease in the United States, Canada 
and Australia.24 It was found that 77% of the respondents were concerned about insurance 
discrimination. In contrast, 44% of the respondents reported concern about discrimination 
in the context of employment. Furthermore, fear of genetic discrimination in insurance 
appears to form a greater hindrance to participation in genetic testing than concern about 
discrimination at work.18, 21, 22, 24, 29, 31, 33, 36 In a Canadian study of Ashkenazi women, 
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Phillips et al. conclude that concern about discrimination in insurance forms a barrier for 
participation for 28% of the respondents, whereas only 8% of those questioned reported 
that the possibility of discrimination by employers is an impediment to getting tested for 
the BRCA1/2 gene.33 The fact that fears for genetic discrimination in insurance are 
relatively high, should come as no surprise. Otlowski et al.15 state that insurance has a 
high potential psychological and social value for those who are insured.50 Being insured 
can have a considerable influence on the welfare and opportunities of those insured.  
Notwithstanding that insurance discrimination seems of greater concern than 
employment discrimination, concerns are quite elevated in the latter context as well. This 
could be illustrated by a quote in the study of Rose et al.36 As an interviewee in this study 
told: “I don’t think there are adequate laws to protect people who may have gotten a 
positive result. First, health records are not kept private. So somebody who has a positive 
result doesn’t have any reassurance that the information would [not] get into the wrong 
hands. Also there really aren’t any laws making it illegal to discriminate against someone 
because of this, like employers and health insurance companies” (p. 148). 
Furthermore, it appears that potential discrimination within one's own family or other 
personal interactions also raises considerable concern.18, 24, 42, 47 Lemke refers to this as 
‘interactional discrimination’.8 In a study by Bombard et al., this concern together with 
the fear of discrimination in insurance was the most mentioned.42 Brendan, an interviewee 
who tested positive for Huntington’s disease, feared stigmatisation and said in the 
interview: “Huntington’s is something that I would be concerned to just blurt out in a 
social setting because it would change the way people think.. I mean that would change 
things immensely… that would absolutely change how people deal with me” (p. 286). 
Interactional discrimination has been much less studied than other contexts in which 
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genetic discrimination can be expressed.8 This kind of discrimination is characterised by 
more spontaneous forms of stigmatisation or disrespect.8 This was indicated in the study 
of Klitzman as well.11 Discrimination can be very subtle and not visible. This makes it 
hard to prove. One woman stated: “I just was worried about being viewed differently… I 
don’t know if discrimination is the right word – but it’s probably the best word” (p. 72). 
These subtle forms of discrimination can have a major impact on people’s lives as well 
(e.g. not undergoing a genetic test, influencing life decisions like moving or changing 
jobs). Because of this, additional stress might arise and this potentially provokes illness.  
Legislation is unable to (completely) alleviate or prevent fears for genetic 
discrimination 
Several studies included in this systematic literature review have investigated the impact 
of legislation on fears and concerns for genetic discrimination.11, 26, 39, 43, 47, 51, 52 The 
American study of Allain et al. specifically investigated the influence of the Genetic 
Information Nondiscrimination Act (2008; GINA), the American law to provide 
protection with regard to health insurance and employment, on genetic testing for 
BRCA1/2 mutations.19 Fear for insurance discrimination was the second most common 
reason to decline genetic testing. Furthermore, it was found that more than half of the 
respondents were not aware of GINA. As part of the study, all respondents were informed 
about GINA and its protection. The majority of respondents indicated that the information 
about GINA made them less worried about insurance discrimination. However, Allain et 
al. argue that awareness of legislation will not completely alleviate fears. As mentioned 
before, genetic discrimination is often subtle, subjective and difficult to prove.11 
Legislation might not be able to react adequately to these forms of discrimination. In 
addition, the results of Allain et al.’s study show that people have questions about how 
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GINA will be enforced. Educating people about GINA seems a simple task, whereas 
creating trust in this legislation is more difficult.  
So, as found by Allain et al., lack of awareness about legislation is not the only reason 
to be concerned about discrimination. A non-American study that is interesting in this 
regard is the Dutch study of Geelen et al.51 Despite Dutch regulations to forbid genetic 
discrimination this study has shown that people still fear genetic discrimination. 
Therefore Geelen et al., have attempted to create more clarity regarding the origin of fears 
for genetic discrimination. The personal stories of six families suggest that negative 
experiences of life with illness in the family led to some postponing genetic testing or 
regretting having undergone testing or. These testimonies suggest that fear for genetic 
discrimination does not result from the possibility to undergo testing or not. The earlier 
negative experiences of living in a family with disease made relatives worry about genetic 
discrimination. So, other forms of disadvantaged treatment and stigmatisation than purely 
genetic discrimination seem to prompt fear in these families. The story of the Goldfield 
family helps to clarify this. After family member Ted was diagnosed with clinically 
manifest hypertrophic cardiomyopathy his life-insurer charged him an extremely high 
premium and Ted's ability to continue performing his job as truck driver was cast in doubt. 
Out of fear that they too might be treated in the same way after a positive result, several 
family members decided not to undergo genetic testing. As stated by Ted’s relative: ‘You 
might be restricted in all your actions and refused by insurance; so what the eye doesn’t 
see, the heart doesn’t grieve over. If you really don’t know about being predisposed to 
increased thickness of the myocardium, you don’t commit insurance fraud when saying 
you are healthy.’ Geelen et al. then argue that it is comprehensible that genetic non-
discrimination regulations are not the right answer to alleviate fears of genetic 
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discrimination. These laws emphasise the novelty and special character of genetic 
discrimination. Geelen et al.'s research however demonstrates that families, even before 
coming into contact with the genetic part of the illness, will already have to deal with 
many other forms of stigmatisation and discrimination and regulations do not cope with 
these experiences. In addition, Geelen et al. suggest that the fear of genetic discrimination 
does not seem directly related to exclusion from insurance or employment but to larger 
concerns of privacy protection and disclosure of issues that are preferred to be kept as 
‘family secrets’. The importance of family experiences on concerns of genetic 
discrimination was observed in a Canadian study as well.42 Individuals at risk for 
Huntington disease became aware of genetic discrimination through symptomatic 
relatives’ experiences of stigma and discrimination.  
Furthermore, Geelen et al. came to another interesting conclusion.51 It is argued that 
the strict distinction between genetic and non-genetic information, that is made in 
legislation and in the classic definition of genetic discrimination, is not always clear for 
the affected families. In another American study, the interviewed patients and their family 
members did not appear to see the distinction between symptomatic and non-
asymptomatic individuals as sharply neither.11 Moreover, it was argued that the disorders 
themselves have ‘grey zones’. This refers to the possible and / or non-specific symptoms 
of diseases that appear often before the disease is really diagnosed, but these might cause 
discrimination as well. In a German study the same conclusion was made.46 Instead of a 
clear distinction, a continuity of discriminatory practices was found.  
To conclude, exclusive protection for genetic information in legislation does not 
appear to be an appropriate answer to concerns about genetic discrimination. Living as a 
person in a family for generations long seems to generate concerns and worries regardless 
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of the specific genetic character of the disease. Therefore it is imperative to focus more 
on family dynamics and individuals experiences of living with the social consequences 
of a disease, than considering awareness regulations as the sole solution.53  
 
DISCUSSION AND CONCLUSION 
In this article, we have explored interesting trends and results in present research about 
genetic discrimination by reviewing existing studies on concerns and fears for genetic 
discrimination in a global context. The results of the 42 included studies all independently 
indicate that a considerable proportion of respondents have concerns or fears of genetic 
discrimination. By reviewing the articles we detected some interesting findings with 
regard to these fears. These results point out where more research is needed. 
First of all, it is suggested that the type of genetic disease may influence the existence 
and size of fears of genetic discrimination. People seem to be highly concerned about 
discrimination in the context of Huntington’s disease. As stated by Klitzman, this is a 
monogenic disease for which no treatment is available and which is associated with a lot 
of stigma and possible discrimination, independent of the genetic character of this 
illness.11 However, individuals at-risk for other, multifactorial diseases (e.g. hereditary 
breast- and ovarian cancer) indicate to be concerned as well. Future research needs to 
examine whether the treatment options and the existence of stigma of different diseases 
may affect if and to what extent people are afraid to be discriminated against and whether 
this influences them in making important life choices (e.g. to undergo genetic testing or 
to move).  
A second trend concerns the context of genetic discrimination. Concerns for genetic 
discrimination appear especially high in the context of insurance and within social 
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relationships. Notwithstanding the high concerns in the context of insurance, 
discrimination in the employment context is often mentioned as well. Interactional 
discrimination has received much less attention in research in comparison with the 
insurance and employment context.8 However, in studies in which this form of 
discrimination was discussed, concerns seemed considerably high. It is suggested that 
interactional discrimination is characterised by more spontaneous forms of stigmatisation 
or disrespect.8 It is often implicit and subtle, which makes it hard to prove. Future research 
needs to incorporate these more implicit and subtle forms of disrespect and stigmatisation 
because they influence the life choices people make.  
Finally, and most importantly, legislation prohibiting genetic discrimination does not 
seem to (completely) alleviate fears of genetic discrimination. In several studies it was 
found that people were not aware of regulation forbidding genetic discrimination. 
Therefore it is often suggested that educating people might alleviate fears of genetic 
discrimination. However, exploratory research into the origins of these fears suggests that 
this lack of awareness on regulation might not be the only reason why people are still 
concerned. Fears seem to arise from pre-existing experiences of living with the social 
consequences of disease in the family.11, 42, 51 For example, the negative treatment of a 
symptomatic relative seems to heighten anxieties among asymptomatic individuals. This 
way, people appear to not distinguish between symptomatic and asymptomatic 
individuals, a distinction that is often made in legislation. Furthermore, diseases often 
have ‘grey zones’: people may be discriminated based on symptoms that are not yet 
recognised as caused by a genetic disorder.  
To conclude, four main recommendations for future research are given. First of all, 
future research has to assess more fully all different forms of genetic discrimination. It 
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seems that not only overt discrimination, but also more subtle and indirect forms of 
discrimination influence the choices individuals make. Secondly, our review suggests that 
knowledge on the origins of fears of genetic discrimination is still very limited. Gaining 
insight in these backgrounds is imperative because this will guide us to effective ways to 
cope with fears of genetic discrimination. Thirdly, people do not seem to make a clear 
distinction between symptomatic and asymptomatic individuals. Future research needs to 
assess whether genetic discrimination represents a form of discrimination that needs to 
be distinguished from discrimination experienced by disabled or chronically ill persons. 
Finally, a last element that should be addressed is the most recent developments in 
research on genomics, such as next-generation sequencing or genome-wide association 
studies. It has now become possible to scan an individual’s genome at a reasonable 
price62. This increases the availability of predictive information. While most studies 
included in this systematic literature review focused on monogenic diseases, it is 
important for future research to study whether and how new genomic tools, such as 
genomic sequencing, will influence the abovementioned issues and the debate on genetic 
discrimination. By incorporating these recommendations in future studies we will be able 
to rethink the concept of genetic discrimination and the protection given to it. 
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